Veralipride

Research use only, not for human use.

Veralipride is an antagonist of D2 receptor.

Veralipride is an antagonist of D2 receptor.

Veralipride administration (100 mg/day for 30 days) induces a significant reduction in vasomotor symptoms and is more effective than placebo. Treatment is followed by the expected increase in plasma prolactin levels and by a significant decrease in mean plasma LH. A significant reduction is observed in objectively recorded hot flushes after Veralipride treatment. Veralipride is well absorbed when administered orally, achieving maximal concentrations at 2.5 hours. It is poorly metabolized and is eliminated in the urine and feces. After oral administration, the half-life is 4 hours, and 44% is excreted without any changes in urine in the first 120 hours. A total of 57 adverse events are registered during the 386-month treatment. For the 20×10 dosing schedule, the highest incidence is observed for anxiety (2.2%), drowsiness, and weakness (1.5%); for the 5 × 2 dosing schedule, the highest incidence is observed for drowsiness (5.3%) and headache (2.6%). Veralipride is known to cause extrapiramidal signs such as bucco-facial or limb dyskinesia. Veralipride may cause reversible parkinsonism.

——

(±)-Veralipride | LIR166

GPCR/G Protein

Dopamine Receptor

D2

——

——

66644-81-3

383.46

C17H25N3O5S

>98% (HPLC)

DMSO:100 mg/mL (260.78 mM)

C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC

N-((1-allylpyrrolidin-2-yl)methyl)-23-dimethoxy-5-sulfamoylbenzamide

(-20℃)

With Ice Pack

≥ 2 years